Endocrine therapies in breast cancer /

Saved in:
Bibliographic Details
Imprint:Oxford ; New York : Oxford University Press, 2007.
Description:1 online resource (viii, 120 pages) : illustrations
Language:English
Series:Oxford oncology library
Oxford oncology library.
Subject:
Format: E-Resource Book
URL for this record:http://pi.lib.uchicago.edu/1001/cat/bib/11138879
Hidden Bibliographic Details
Other authors / contributors:Buzdar, Aman U.
ISBN:9780191575174
0191575178
9780199218141
0199218145
Notes:Includes bibliographical references and index.
Print version record.
Summary:Breast cancer is one of the leading causes of cancer mortality in women worldwide, and the risk of disease recurrence continues despite improvements in screening and treatment. For patients with hormone receptor-positive breast cancer, some form of endocrine therapy is central to the management of their disease. Tamoxifen has long been the mainstay of endocrine therapy in this group of patients. However, there is mounting evidence showing that the aromatase inhibitors are able toreduce overall oestrogen levels and appear to be better tolerated over a long term than tamoxifen. New and emerging.
Other form:Print version: Endocrine therapies in breast cancer. Oxford ; New York : Oxford University Press, 2007 9780199218141

MARC

LEADER 00000cam a2200000Ka 4500
001 11138879
006 m o d
007 cr cnu---unuuu
008 120723s2007 enka ob 001 0 eng d
005 20240510212901.2
010 |z  2007038907 
019 |a 801363649  |a 961618370  |a 962602314  |a 966212272  |a 988501072  |a 992094670  |a 1037791981  |a 1038614370  |a 1045514218  |a 1055366187  |a 1066545960  |a 1081286810  |a 1153554442 
020 |a 9780191575174  |q (electronic bk.) 
020 |a 0191575178  |q (electronic bk.) 
020 |z 9780199218141 
020 |z 0199218145 
035 |a (OCoLC)801405943  |z (OCoLC)801363649  |z (OCoLC)961618370  |z (OCoLC)962602314  |z (OCoLC)966212272  |z (OCoLC)988501072  |z (OCoLC)992094670  |z (OCoLC)1037791981  |z (OCoLC)1038614370  |z (OCoLC)1045514218  |z (OCoLC)1055366187  |z (OCoLC)1066545960  |z (OCoLC)1081286810  |z (OCoLC)1153554442 
035 9 |a (OCLCCM-CC)801405943 
040 |a N$T  |b eng  |e pn  |c N$T  |d E7B  |d OCLCQ  |d OCLCF  |d OCLCQ  |d NLGGC  |d OCLCO  |d YDXCP  |d OCLCQ  |d EBLCP  |d IDEBK  |d OCLCO  |d OCLCQ  |d AZK  |d OCLCO  |d LOA  |d UKOUP  |d OCLCA  |d COCUF  |d TOA  |d OCLCO  |d AGLDB  |d OCLCO  |d MOR  |d CCO  |d PIFAG  |d ZCU  |d OCLCO  |d OCLCQ  |d MERUC  |d OCLCO  |d OCLCQ  |d OCLCO  |d OCLCA  |d U3W  |d OCLCO  |d STF  |d OCLCO  |d WRM  |d VNS  |d OCLCO  |d VTS  |d NRAMU  |d ICG  |d VT2  |d AU@  |d OCLCO  |d OCLCQ  |d WYU  |d OCLCA  |d REC  |d OCLCO  |d DKC  |d OCLCQ  |d UX1  |d OCLCQ  |d OCLCA  |d UKCRE  |d UKAHL  |d AJS 
049 |a MAIN 
050 4 |a RC280.B8  |b E523 2007eb 
060 4 |a WP 870  |b E56 2007 
072 7 |a HEA  |x 039030  |2 bisacsh 
072 7 |a MED  |x 062000  |2 bisacsh 
245 0 0 |a Endocrine therapies in breast cancer /  |c edited by Aman U. Buzdar. 
260 |a Oxford ;  |a New York :  |b Oxford University Press,  |c 2007. 
300 |a 1 online resource (viii, 120 pages) :  |b illustrations 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
490 1 |a Oxford oncology library 
504 |a Includes bibliographical references and index. 
505 0 |a Selection of patients for endocrine therapies / W. Fraser Symmans and Lajos Pusztai -- Ovarian ablation / Kellie l. Jones -- Antioestrogens / John F. Forbes -- Aromatase inhibitors in early and advanced disease / Laura Boehnke Michaud -- Fulvestrant in metastatic disease / Amit Agrawal, J.F.R. Robertson, and K.L. Cheung -- Progestins and androgens / Janet l. Espirito -- Combined endocrine and chemotherapy in breast cancer / Ishmael Jaiyesimi [and others] -- Hormone replacement therapy in patients with a prior history of breast cancer / Gilbert G. Fareau and Rena Vassilopoulou-Sellin -- Chemoprevention / Saheenah Dawood and Jack Cuzick. 
588 0 |a Print version record. 
520 |a Breast cancer is one of the leading causes of cancer mortality in women worldwide, and the risk of disease recurrence continues despite improvements in screening and treatment. For patients with hormone receptor-positive breast cancer, some form of endocrine therapy is central to the management of their disease. Tamoxifen has long been the mainstay of endocrine therapy in this group of patients. However, there is mounting evidence showing that the aromatase inhibitors are able toreduce overall oestrogen levels and appear to be better tolerated over a long term than tamoxifen. New and emerging. 
650 0 |a Breast  |x Cancer  |x Hormone therapy. 
650 0 |a Breast  |x Cancer  |x Endocrine aspects. 
650 1 2 |a Breast Neoplasms  |x drug therapy. 
650 2 2 |a Antineoplastic Agents, Hormonal  |x therapeutic use. 
650 7 |a HEALTH & FITNESS  |x Diseases  |x Cancer.  |2 bisacsh 
650 7 |a MEDICAL  |x Oncology.  |2 bisacsh 
650 7 |a Breast  |x Cancer  |x Endocrine aspects.  |2 fast  |0 (OCoLC)fst00838273 
650 7 |a Breast  |x Cancer  |x Hormone therapy.  |2 fast  |0 (OCoLC)fst00838281 
655 0 |a Electronic books. 
655 4 |a Electronic books. 
700 1 |a Buzdar, Aman U. 
776 0 8 |i Print version:  |t Endocrine therapies in breast cancer.  |d Oxford ; New York : Oxford University Press, 2007  |z 9780199218141  |w (DLC) 2007038907  |w (OCoLC)74966478 
830 0 |a Oxford oncology library.  |0 http://id.loc.gov/authorities/names/n2007184279 
903 |a HeVa 
929 |a oclccm 
999 f f |i 7c29eddb-303d-5286-b4b6-5c82eb74db0a  |s b02da9e6-f0ae-584b-96d0-041b1b295f13 
928 |t Library of Congress classification  |a RC280.B8 E523 2007eb  |l Online  |c UC-FullText  |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=e000xna&AN=467600  |z eBooks on EBSCOhost  |g ebooks  |i 12372727